Perspective Therapeutics investor call on VMT-α-NET data at ESMO Congress 2026 - PERSPECTIVE THERAPEUTICS INC

Explicit Guidance:

• No specific quantitative financial guidance (revenue, earnings, margins, capex) provided.
• Regulatory Milestone Timing: Management targets readiness for an FDA End-of-Phase 2 meeting later this year (2026).
• Pivotal Study Initiation: Aiming to initiate a registrational Phase 3 study early next year (2027).
• Future Data Presentation: An oral presentation with longer follow-up is expected at the NANETS Conference in "several weeks" (late 2026).

Business-Segment Outlook:

• Lead Asset (VMT AlphaNet):
  • Target Population: Focus on the "GAPNET" cohort (gastroenteropancreatic neuroendocrine tumors) where all lesions are SSTR2-positive.
  • Efficacy Signal: Anticipates 37–47% Overall Response Rates (ORR) in this enriched population (based on Cohort 2 and 3 data) versus ~13% ORR for current standards like Lutathera.
  • Disease Control: Projecting a 72% landmark Progression-Free Survival (PFS) rate at 18 months in the target cohort.
  • Dose Selection: Management favors the 20 millicurie dose (Cohort 2) for Phase 3 initiation due to favorable benefit-risk profile and data maturity; however, a pre-specified protocol may allow automatic escalation to the 24 millicurie dose (Cohort 3) once that data is available.
  • Safety Profile: Expected to maintain a safe profile with no dose-limiting toxicities, no grade 4/5 adverse events, and low incidence of dysphagia or myelosuppression.
• Pipeline Assets:
  • VMT01 (Lap and Melanotide): Expectation to release dose escalation data in the near term.
  • Other Programs: Active development in FAP and CCQ2R indications.

Market and Competitive Outlook:

• Unmet Need: Addresses a market of ~250,000 patients with NETs in the US, with 12,000 new diagnoses annually; 90% express SSTR2.
• Competitive Positioning: Aims to be "category-defining" by offering deeper responses and more durable disease control compared to somatostatin analogs and current radioligands (e.g., Lutathera, Neter1).
• Standard of Care Comparison: Anticipates superior disease control compared to current options including Lutathera, Sunitinib, Cabozantinib, and Everolimus.
• Market Access Strategy: The pivotal Phase 3 trial is expected to utilize a "Physician's Choice" comparator arm to reflect real-world treatment patterns (including PRT, small molecules, and chemotherapy).
• Labeling: Anticipates approval based on disease control (PFS) as the primary endpoint, with potential for accelerated approval or Breakthrough Therapy designation based on Overall Response Rate (ORR) and depth of response.

Macro / Industry Outlook:

• Regulatory Pathway: Utilizing FDA Fast-Track designation and eligibility for the Complex Drug Research Program (CDRP).
• Clinical Trial Design: Emphasis on enrolling patients with homogeneous SSTR2 expression to maximize trial success and minimize early progressors in the registrational setting.
• Safety Monitoring: Plan to incorporate specific monitoring and hydration protocols into the Phase 3 design to mitigate acute kidney injury risks observed in early cohorts.

Strategic Initiatives:

• Phase 3 Launch: Commitment to organizational readiness by the end of 2026 to support Phase 3 initiation in early 2027.
• Dose Optimization: Continued dosing in Cohort 4 (a variation of the 20 millicurie dose) to further validate the therapeutic window.
• Data Maturity: Aggressively tracking "late" responses (up to 60 weeks) to refine ORR estimates and confirm unconfirmed responses.
• Patient Enrollment: Strong demand from patients and clinicians for inclusion in upcoming cohorts.

Risks and Headwinds to Outlook:

• Acute Kidney Injury (AKI): Observed Grade 3 AKI events in early cohorts; potential exclusion of patients with pre-existing renal comorbidities (e.g., hypertension, diabetes, prior AKI) from Phase 3.
• Patient Heterogeneity: Enrolled patients with heterogeneous SSTR2 expression may underperform in the registrational trial; exclusion criteria may be tightened to require all lesions to be SSTR2-positive.
• Data Immaturity: Current PFS and ORR data are derived from immature datasets (limited follow-up in Cohort 3); final registrational numbers may fluctuate as follow-up extends.
• Comparative Limitations: Early trial results are not directly comparable to mature Phase 3 data (e.g., Netter-1, Netter-2) due to differences in patient selection and study design.
• Delayed Response Kinetics: Slow tumor shrinkage on CT scans due to the biology of neuroendocrine tumors ("slow growing, slow dying") may delay the appearance of confirmed ORR, requiring reliance on disease control metrics for interim success.

Management Tone on the Future:

• Confidence Level: High. Management expresses "extreme excitement" and "conviction" in the data profile.
• Strategic Clarity: Clear preference for the 20 millicurie dose for initial Phase 3 entry, with a defined path to escalate to 24 millicuries.
• Stakeholder Sentiment: Describes clinicians as "very excited" and patients as eager to join trials, citing a "compelling benefit-risk trade-off."
• Hedges: Acknowledges the need for more follow-up to confirm unconfirmed responses and the necessity of refining inclusion criteria for the Phase 3 registry.

Miscellaneous:

• Total Patients Treated: Over 150 patients worldwide to date.
• Safety Specifics: Zero grade 4/5 adverse events; zero treatment discontinuations due to adverse events; no dysphagia observed.
• Mechanism of Action: Distinction made regarding the "double-stranded DNA break" efficacy of alpha particles versus beta particles, highlighting the potential for cell death even if shrinkage is delayed on imaging.